Hesari Parisa M, James Drexler, Lizotte Daniel J, Bauer Greta R
Department of Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada.
Department of Psychology, University of Minnesota, London, ON, Canada.
Epidemiol Rev. 2025 Jan 10;47(1). doi: 10.1093/epirev/mxaf009.
For interventions aimed at redressing health disparities in breast cancer to be effective, a clear understanding of the nature and causes of these disparities is required. Our questions were: what is the current evidence for ethnoracial disparities in time-to-treatment initiation and survival in breast cancer, and how are the causal mechanisms of these disparities conceptualized in the literature? A comprehensive systematic search of studies on cohorts of female patients with breast cancer diagnosed with stage I-III was performed. Directed acyclic graphs were used to describe implicit causal relationships between racial/ethnic group membership and time-to-treatment initiation and survival outcomes. This review revealed strong evidence for ethnoracial disparities in both time to treatment and survival among patients with breast cancer. Unmeasured factors identified by the authors highlighted gaps in data sources and opportunities for causal reasoning. Although the existing literature describes ethnoracial disparities, there is very limited discussion of causal mechanisms and no discussion of system-level rather than individual-level effects. Addressing established ethnoracial disparities in breast cancer requires new research that explicitly considers the causal mechanisms of potential interventions, incorporating unmeasured factors contributing to these disparities. Trial registration: PROSPERO identifier: CRD42023391901.
为使旨在消除乳腺癌健康差异的干预措施有效,需要清楚了解这些差异的性质和成因。我们的问题是:关于乳腺癌治疗开始时间和生存率方面种族差异的现有证据是什么,以及这些差异的因果机制在文献中是如何被概念化的?我们对诊断为I - III期的女性乳腺癌患者队列研究进行了全面的系统检索。使用有向无环图来描述种族/族裔群体成员身份与治疗开始时间和生存结果之间的隐含因果关系。本综述揭示了乳腺癌患者在治疗时间和生存率方面存在种族差异的有力证据。作者识别出的未测量因素凸显了数据源方面的差距以及因果推理的机会。尽管现有文献描述了种族差异,但对因果机制的讨论非常有限,且未讨论系统层面而非个体层面的影响。解决已确定的乳腺癌种族差异问题需要新的研究,明确考虑潜在干预措施的因果机制,并纳入导致这些差异的未测量因素。试验注册:PROSPERO标识符:CRD42023391901。
Cochrane Database Syst Rev. 2018-9-19
Health Technol Assess. 2006-9
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2022-1-10
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2025-6-19
Ann Surg Oncol. 2023-9
Am J Surg. 2023-10
J Natl Cancer Inst. 2023-6-8
Breast Cancer Res Treat. 2023-2
Anticancer Res. 2022-12
Ann Surg Oncol. 2022-11
N Engl J Med. 2022-6-23